Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551885 · ClinicalTrials.gov registry record · Phase 1
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04551885 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT04551885, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG IL-2
- DRUG Avelumab
- DRUG FT516
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-09-07 |
| Est. Completion | 2023-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04551885
The ClinicalTrials.gov registry entry for NCT04551885 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04551885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04551885 about?
NCT04551885 is a clinical study titled "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors". This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
What is the current status of trial NCT04551885?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-09-07. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT04551885?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IL-2 (DRUG), Avelumab (DRUG), FT516 (DRUG).
Who is sponsoring clinical trial NCT04551885?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.